| Title |
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology
|
|---|---|
| Published in |
Annals of Surgical Oncology, July 2018
|
| DOI | 10.1245/s10434-018-6598-z |
| Pubmed ID | |
| Authors |
Danielle M. Bello, Christy Russell, Debbie McCullough, Marni Tierno, Monica Morrow |
| Abstract |
The 21-gene Oncotype DX® Breast Recurrence Score® (RS) assay has been prospectively validated as prognostic and predictive in node-negative, estrogen receptor-positive (ER+)/HER2- breast cancer patients. Less is known about its prognostic role in node-positive breast cancer. We compared RS results among patients with lymph node-negative (N0), micrometastatic (N1mi), and macrometastatic (N+) breast cancer to determine if nodal metastases are associated with more aggressive biology, as determined by RS. Overall, 610,350 tumor specimens examined by the Genomic Health laboratory from February 2004 to August 2017 were studied. Histology was classified centrally, while lymph node status was determined locally. RS distribution (low: < 18; intermediate: 18-30; high: ≥ 31) was compared by nodal status. Eighty percent (n = 486,013) of patients were N0, 4% (n = 24,325) were N1mi, 9% (n = 56,100) were N+, and 7% (n = 43,912) had unknown nodal status. Mean RS result was 18, 16.7, 17.3 and 18.9 in the N0, N1mi, N+, and unknown groups, respectively. An RS ≥ 31 was seen in 10% of N0 patients, 7% of N1mi patients, and 8.0% of N+ patients. The likelihood of an RS ≥ 31 in N1mi and N+ patients varied with tumor histology, with only 2% of patients with classic infiltrating lobular cancer having an RS ≥ 31, versus 7-9% of those with ductal carcinoma. RS distribution among N0, N1mi, and N+ patients is similar, suggesting a spectrum of biology and potential chemotherapy benefit exists among node-negative and node-positive ER+/HER2- breast cancer patients. If RxPONDER does not show a chemotherapy benefit in N+ patients with a low RS result, our findings indicate that substantial numbers of patients could be spared the burden of chemotherapy. |
X Demographics
The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 9 | 26% |
| United States | 8 | 24% |
| Canada | 1 | 3% |
| Brazil | 1 | 3% |
| Libya | 1 | 3% |
| Guatemala | 1 | 3% |
| Sweden | 1 | 3% |
| Venezuela, Bolivarian Republic of | 1 | 3% |
| Ecuador | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 7 | 21% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 22 | 65% |
| Practitioners (doctors, other healthcare professionals) | 7 | 21% |
| Scientists | 4 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 13% |
| Student > Bachelor | 2 | 8% |
| Student > Ph. D. Student | 2 | 8% |
| Researcher | 2 | 8% |
| Lecturer | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 10 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 25% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Agricultural and Biological Sciences | 1 | 4% |
| Engineering | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 12 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2023.
All research outputs
#1,220,373
of 25,089,705 outputs
Outputs from Annals of Surgical Oncology
#150
of 7,163 outputs
Outputs of similar age
#25,895
of 334,138 outputs
Outputs of similar age from Annals of Surgical Oncology
#11
of 125 outputs
Altmetric has tracked 25,089,705 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,163 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.